Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma
Annals of Hematology · 09.05.2026 · 105 (7)
DOI: 10.1007/s00277-026-07047-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 09.05.2026. Verfasst von Salvatore Perrone und 22 weiteren Autor:innen. Beteiligte Einrichtung: , Hematology, Polo Universitario Pontino, "Sapienza", Via A. Canova S.M. Goretti Hospital, Latina, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Autoimmune Diseases, Infections, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.
Abstract (Originalsprache)
Rituximab is employed in the treatment of B-cell non-Hodgkin lymphomas (NHL) and autoimmune disorders of hematological interest (ADHI), such as autoimmune hemolytic anemia (AIHA), acquired hemophilia A (AHA), and immune thrombocytopenia (ITP). Rituximab induces profound B-cell depletion, reducing the titer of immunoglobulins and autoreactive antibodies, but secondary hypogammaglobulinemia increases risk of infections. We performed a retrospective, multicentric study across seven Italian centers to compare two cohorts of patients with either indolent NHL or ADHI treated with rituximab between March 2014 and March 2024. We evaluated the incidence and characteristics of infections and common antimicrobial prophylaxis adopted according to local clinical practice, in the absence of shared guidelines for ADHI. We included 285 patients (52% female; median age 55 years). The ADHI cohort comprised 187 patients (65%; 97 ITP, 78 AIHA, 12 AHA), while the control group included 98 i-NHL patients (34%). We documented 65 infectious events occurring in 65/285 patients (22.8%). Infection-related mortality occurred in 9 patients (4%). When stratified, the cumulative 180-day incidence of infections was 9.4% (IC95% 8.8%-10%) for NHL patients and 13.7% for ADHI (IC95% 12.2%-14.2%). Multivariate analysis identified prophylaxis (OR 2.62, p = 0.014) and post-treatment hypogammaglobulinemia (OR 2.73 p = 0.004) as risk factors. The risk of infection in patients with ADHI is high and comparable to that observed in NHL. Therefore, close monitoring of IgG levels is strongly advised, and mortality can be contained through rigorous antimicrobial stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- , Hematology, Polo Universitario Pontino, "Sapienza", Via A. Canova S.M. Goretti Hospital, Latina, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Via del Vespro 129, Palermo, 90127, Italy.
- Hematology and Rare Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy. simona.raso86@gmail.com.
- Division of Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, Roma, Italy.
- Department of precision medicine in medical, surgical and critical care (Me.Pre.Cc), University of Palermo, Raffadali, Italy.
- Division of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Förderung
- Università degli Studi di Palermo
Zitieren
APA
Perrone, S., Tomasello, R., Raso, S., Annibali, O., Tafuri, M., Mattana, M., Soriano, T., Fanciullo, D., Assanto, G. M., Pedone, G. L., Baldacci, E., Santacroce, E., Markovic, U., Giuffrida, G., Ingrascì, M. G., Biglietto, M., Cammarata, C., Totaro, M., Ligia, S., …, & Napolitano, M. (2026). Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07047-4
Vancouver
Perrone S, Tomasello R, Raso S, Annibali O, Tafuri M, Mattana M, et al. Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07047-4
BibTeX
@article{Perrone2026,
author = {Perrone, Salvatore and Tomasello, Riccardo and Raso, Simona and Annibali, Ombretta and Tafuri, Mariantonietta and Mattana, Marta and Soriano, Tania and Fanciullo, David and Assanto, Giovanni Manfredi and Pedone, Giacinto Luca and Baldacci, Erminia and Santacroce, Eugenio and Markovic, Uros and Giuffrida, Gaetano and Ingrascì, Manuela Giuseppa and Biglietto, Mario and Cammarata, Claudia and Totaro, Matteo and Ligia, Silvio and Fattizzo, Bruno and Santoro, Cristina and Siragusa, Sergio and Napolitano, Mariasanta},
title = {Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {7},
doi = {10.1007/s00277-026-07047-4}
}
EUVIMED